Tribe Technology set to deliver healthy pipeline of orders from Tier-One miners. Watch the video here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksGlaxosmithkline Regulatory News (GSK)

Share Price Information for Glaxosmithkline (GSK)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 1,529.50
Bid: 1,531.50
Ask: 1,532.00
Change: 3.50 (0.23%)
Spread: 0.50 (0.033%)
Open: 1,537.00
High: 1,541.50
Low: 1,523.00
Prev. Close: 1,526.00
GSK Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

Block listing Interim Review

9 Nov 2017 17:00

RNS Number : 1021W
GlaxoSmithKline PLC
09 November 2017
 

 

 

 

BLOCK LISTING SIX MONTHLY RETURN

 

Information provided on this form must be typed or printed electronically and provided to an ris.

 

Date: 09 November 2017

 

Name of applicant:

GlaxoSmithKline plc

Name of scheme:

GlaxoSmithKline Share Option Plan - Ordinary Shares

Period of return:

From:

1 May 2017

To:

31 October 2017

Balance of unallotted securities under scheme(s) from previous return:

4,104,101

 

Plus: The amount by which the block scheme(s) has been increased since the date of the last return (if any increase has been applied for):

0

Less: Number of securities issued/allotted under scheme(s) during period (see LR3.5.7G):

543,609

Equals: Balance under scheme(s) not yet issued/allotted at end of period:

3,559,772

 

Name of contact:

Victoria Whyte

Telephone number of contact:

020 8047 5000

 

 

 

 

BLOCK LISTING SIX MONTHLY RETURN

 

Information provided on this form must be typed or printed electronically and provided to an ris.

 

Date: 09 November 2017

 

Name of applicant:

GlaxoSmithKline plc

Name of scheme:

GlaxoSmithKline Share Option Plan - ADS

Period of return:

From:

1 May 2017

To:

31 October 2017

Balance of unallotted securities under scheme(s) from previous return:

8,795,814

Plus: The amount by which the block scheme(s) has been increased since the date of the last return (if any increase has been applied for):

0

Less: Number of securities issued/allotted under scheme(s) during period (see LR3.5.7G):

611,414

Equals: Balance under scheme(s) not yet issued/allotted at end of period:

8,185,120

 

Name of contact:

Victoria Whyte

Telephone number of contact:

020 8047 5000

 

 

 

 

 

 

 

BLOCK LISTING SIX MONTHLY RETURN

 

Information provided on this form must be typed or printed electronically and provided to an ris.

 

Date: 09 November 2017

 

Name of applicant:

GlaxoSmithKline plc

Name of scheme:

Glaxo Wellcome UK Share Option Scheme

Period of return:

From:

1 May 2017

To:

31 October 2017

Balance of unallotted securities under scheme(s) from previous return:

5,119,750

Plus: The amount by which the block scheme(s) has been increased since the date of the last return (if any increase has been applied for):

0

Less: Number of securities issued/allotted under scheme(s) during period (see LR3.5.7G):

0

Equals: Balance under scheme(s) not yet issued/allotted at end of period:

5,119,750

 

Name of contact:

Victoria Whyte

Telephone number of contact:

020 8047 5000

 

 

 

 

 

 

 

BLOCK LISTING SIX MONTHLY RETURN

 

Information provided on this form must be typed or printed electronically and provided to an ris.

 

Date: 09 November 2017

 

Name of applicant:

GlaxoSmithKline plc

Name of scheme:

Glaxo Wellcome International Share Option Scheme

Period of return:

From:

1 May 2017

To:

31 October 2017

Balance of unallotted securities under scheme(s) from previous return:

13,267,156

Plus: The amount by which the block scheme(s) has been increased since the date of the last return (if any increase has been applied for):

0

Less: Number of securities issued/allotted under scheme(s) during period (see LR3.5.7G):

0

Equals: Balance under scheme(s) not yet issued/allotted at end of period:

13,267,156

 

Name of contact:

Victoria Whyte

Telephone number of contact:

020 8047 5000

 

 

 

 

 

 

 

 

BLOCK LISTING SIX MONTHLY RETURN

 

Information provided on this form must be typed or printed electronically and provided to an ris.

 

Date: 09 November 2017

 

Name of applicant:

GlaxoSmithKline plc

Name of scheme:

Glaxo Wellcome 1999 Share Option Plan

Period of return:

From:

1 May 2017

To:

31 October 2017

Balance of unallotted securities under scheme(s) from previous return:

1,040,000

Plus: The amount by which the block scheme(s) has been increased since the date of the last return (if any increase has been applied for):

0

Less: Number of securities issued/allotted under scheme(s) during period (see LR3.5.7G):

0

Equals: Balance under scheme(s) not yet issued/allotted at end of period:

1,040,000

 

Name of contact:

Victoria Whyte

Telephone number of contact:

020 8047 5000

 

 

 

 

 

 

 

BLOCK LISTING SIX MONTHLY RETURN

 

Information provided on this form must be typed or printed electronically and provided to an ris.

 

Date: 09 November 2017

 

Name of applicant:

GlaxoSmithKline plc

Name of scheme:

SmithKline Beecham 1989 Executive Share Option Plan - Approved - Ordinary Shares

Period of return:

From:

1 May 2017

To:

31 October 2017

Balance of unallotted securities under scheme(s) from previous return:

163,606

Plus: The amount by which the block scheme(s) has been increased since the date of the last return (if any increase has been applied for):

0

Less: Number of securities issued/allotted under scheme(s) during period (see LR3.5.7G):

0

Equals: Balance under scheme(s) not yet issued/allotted at end of period:

163,606

 

Name of contact:

Victoria Whyte

Telephone number of contact:

020 8047 5000

 

 

 

 

 

 

 

BLOCK LISTING SIX MONTHLY RETURN

 

Information provided on this form must be typed or printed electronically and provided to an ris.

 

Date: 09 November 2017

 

Name of applicant:

GlaxoSmithKline plc

Name of scheme:

SmithKline Beecham 1989 Executive Share Option Plan - Unapproved - ADS

Period of return:

From:

1 May 2017

To:

31 October 2017

Balance of unallotted securities under scheme(s) from previous return:

275,420

Plus: The amount by which the block scheme(s) has been increased since the date of the last return (if any increase has been applied for):

0

Less: Number of securities issued/allotted under scheme(s) during period (see LR3.5.7G):

0

Equals: Balance under scheme(s) not yet issued/allotted at end of period:

275,420

 

Name of contact:

Victoria Whyte

Telephone number of contact:

020 8047 5000

 

 

 

 

 

 

 

BLOCK LISTING SIX MONTHLY RETURN

 

Information provided on this form must be typed or printed electronically and provided to an ris.

 

Date: 09 November 2017

 

Name of applicant:

GlaxoSmithKline plc

Name of scheme:

SmithKline Beecham 1989 Executive Share Option Plan - Unapproved - Ordinary

Period of return:

From:

1 May 2017

To:

31 October 2017

Balance of unallotted securities under scheme(s) from previous return:

100,000

Plus: The amount by which the block scheme(s) has been increased since the date of the last return (if any increase has been applied for):

0

Less: Number of securities issued/allotted under scheme(s) during period (see LR3.5.7G):

0

Equals: Balance under scheme(s) not yet issued/allotted at end of period:

100,000

 

Name of contact:

Victoria Whyte

Telephone number of contact:

020 8047 5000

 

 

 

 

 

BLOCK LISTING SIX MONTHLY RETURN

 

Information provided on this form must be typed or printed electronically and provided to an ris.

 

Date: 09 November 2017

 

Name of applicant:

GlaxoSmithKline plc

Name of scheme:

GlaxoSmithKline plc Share Save Plan 2012

Period of return:

From:

1 May 2017

To:

31 October 2017

Balance of unallotted securities under scheme(s) from previous return:

1,635,325

Plus: The amount by which the block scheme(s) has been increased since the date of the last return (if any increase has been applied for):

0

Less: Number of securities issued/allotted under scheme(s) during period (see LR3.5.7G):

93,255

Equals: Balance under scheme(s) not yet issued/allotted at end of period:

1,542,070

 

Name of contact:

Victoria Whyte

Telephone number of contact:

020 8047 5000

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

BLOCK LISTING SIX MONTHLY RETURN

 

Information provided on this form must be typed or printed electronically and provided to an ris.

 

Date: 09 November 2017

 

Name of applicant:

GlaxoSmithKline plc

Name of scheme:

GlaxoSmithKline plc 2009 Deferred Annual Bonus Plan

Period of return:

From:

1 May 2017

To:

31 October 2017

Balance of unallotted securities under scheme(s) from previous return:

200,071

Plus: The amount by which the block scheme(s) has been increased since the date of the last return (if any increase has been applied for):

0

Less: Number of securities issued/allotted under scheme(s) during period (see LR3.5.7G):

989

Equals: Balance under scheme(s) not yet issued/allotted at end of period:

199,082

 

Name of contact:

Victoria Whyte

Telephone number of contact:

020 8047 5000

 

This information is provided by RNS
The company news service from the London Stock Exchange
 
END
 
 
BLRKMMGMVLLGNZM
Date   Source Headline
28th Jun 20245:37 pmRNSStatement: Zantac (ranitidine) litigation
24th Jun 20247:05 amRNSOmjjara approved in Japan for myelofibrosis
24th Jun 20247:00 amRNSEMA validates Jemperli marketing authorisation
21st Jun 20243:30 pmRNSDirector/PDMR Shareholding
12th Jun 20243:30 pmRNSDirector/PDMR Shareholding
11th Jun 20247:00 amRNSStatement: Zantac (ranitidine) litigation
10th Jun 20246:27 pmRNSStatement: Zantac (ranitidine) litigation
10th Jun 20247:00 amRNSFDA approves Arexvy for adults 50-59 at risk
3rd Jun 20243:00 pmRNSTotal Voting Rights
3rd Jun 20241:03 pmRNSUnprecedented results in Jemperli trial continue
3rd Jun 20247:05 amRNSASCO positive Blenrep DREAMM-8 trial results
3rd Jun 20247:00 amRNSStatement: Zantac (ranitidine) litigation
24th May 20247:00 amRNSStatement: Zantac (ranitidine) litigation
21st May 20247:00 amRNSPositive phase III asthma results for depemokimab
20th May 20243:30 pmRNSDirector/PDMR Shareholding
17th May 20247:00 amRNSGSK completes sale of shares in Haleon plc
16th May 20244:42 pmRNSGSK announces intention to sell shares in Haleon
14th May 20243:30 pmRNSDirector/PDMR Shareholding
13th May 20243:00 pmRNSBlock listing Interim Review
8th May 20246:21 pmRNSResult of AGM
8th May 20244:57 pmRNSBoard Committee Change
3rd May 20243:30 pmRNSDirector/PDMR Shareholding
1st May 20243:00 pmRNSTotal Voting Rights
1st May 20247:00 amRNS1st Quarter Results
24th Apr 20247:00 amRNSUS FDA accepts new indication filing for Jemperli
19th Apr 20243:30 pmRNSDirector/PDMR Shareholding
17th Apr 20243:30 pmRNSDirector/PDMR Shareholding
17th Apr 20247:05 amRNSGSK announces additional EAGLE-1 results
17th Apr 20247:00 amRNSResults from long-term data relating to Shingrix
16th Apr 20242:11 pmRNSAmendment - Director/PDMR Shareholding
16th Apr 20247:00 amRNSFDA accepts GSK meningitis vaccine candidate file
15th Apr 20243:30 pmRNSDirector/PDMR Shareholding
4th Apr 202412:05 pmRNSReplacement - Total Voting Rights
2nd Apr 20243:00 pmRNSTotal Voting Rights
26th Mar 20243:30 pmRNSDirector/PDMR Shareholding
25th Mar 20241:00 pmRNSNotice of AGM
22nd Mar 20244:20 pmRNSTransfer of Treasury Shares
22nd Mar 20243:36 pmRNSDirector/PDMR Shareholding
18th Mar 20249:30 amRNSNew Phase III Jemperli data in endometrial cancer
13th Mar 20243:48 pmRNSDirector/PDMR Shareholding
8th Mar 20245:12 pmRNSBoard Committee Change
7th Mar 20247:00 amRNSGSK announces positive Blenrep DREAMM-8 results
6th Mar 20244:00 pmRNSViiV LAI vs oral SOC data in adherence-challenged
5th Mar 20245:24 pmRNSGSK Annual Report 2023 on Form 20-F
5th Mar 20247:00 amRNSNew ViiV LA formulation potential 4-month dosing
1st Mar 20243:00 pmRNSTotal Voting Rights
1st Mar 202412:15 pmRNSGSK publishes Annual Report 2023
29th Feb 20247:05 amRNSDirectorate Change
29th Feb 20247:00 amRNSStatement: Zantac (ranitidine) litigation
26th Feb 20243:30 pmRNSDirector/PDMR Shareholding

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.